Medicinal opium preparations

Generic Medicine Info
Hypersensitivity. Convulsion (e.g. status epilepticus, tetanus, strychnine poisoning), diarrhoea caused by poisoning. Concomitant or within 14 days of MAOI use.
Special Precautions
Patient with history and risk factors for drug dependence; morbid obesity, alcoholism, hypovolaemia, CV disease (e.g. MI), acute abdominal conditions, hypoxia, glaucoma, CNS or respiratory depression, cerebral injury or arteriosclerosis, intracranial lesions, high intracranial pressure, delirium tremens, asthma, emphysema, gastrointestinal haemorrhage, biliary tract dysfunction (e.g. acute pancreatitis), urethral stricture (e.g. prostatic hypertrophy), Addison's disease, hypothyroidism. Hepatic and renal impairment. Children. Pregnancy and lactation. Surgery. Avoid abrupt withdrawal. Patient Counselling This drug may impair mental and/or physical abilities, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure. Assess for signs and symptoms of drug dependence, CNS or respiratory depression.
Adverse Reactions
Significant: Drug dependence, apnoea, hypotension. Eye disorders: Miosis. Gastrointestinal disorders: Nausea, vomiting, constipation, dry mouth. General disorders and administration site conditions: Asthenia. Immune system disorders: Urticaria. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Lightheadedness, dizziness, drowsiness, sedation. Psychiatric disorders: Confusion, euphoria, dysphoria. Renal and urinary disorders: Urinary retention. Respiratory, thoracic and mediastinal disorders: Bronchospasms. Skin and subcutaneous tissue disorders: Pruritus. Vascular disorders: Flushing.
Potentially Fatal: Severe respiratory depression; increased intracranial pressure.
Drug Interactions
May cause increased CNS or respiratory depression with other narcotic analgesics, general anaesthetics, sedative/hypnotic, antihistamines, phenothiazines, or other CNS depressants. May cause decreased effect or increased withdrawal symptoms with other morphine agonists/antagonist (e.g. buprenorphine, nalbuphine, pentazocine). Decreased effect with CYP3A4 inducer (e.g. rifampicin). Increased toxicity of squill with concomitant diuretics.
ATC Classification
N02AA02 - opium ; Belongs to the class of natural opium alkaloids. Used to relieve pain.
A07DA02 - opium ; Belongs to the class of antipropulsives. Used in the treatment of diarrhea.
Disclaimer: This information is independently developed by CIMS based on medicinal opium preparations from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in